Back to top
more

Universal Health Services (UHS)

(Delayed Data from NYSE)

$189.34 USD

189.34
410,075

-0.13 (-0.07%)

Updated Jun 6, 2024 04:00 PM ET

After-Market: $189.22 -0.12 (-0.06%) 7:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 11% (28 out of 248)

Industry: Medical - Hospital

Better trading starts here.

Zacks News

Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging

Philips' (PHG) latest X11-4t Mini 3D TEE transducer is likely to have an edge over the traditional 3D TEE in terms of catering to a broader range of patients and improved overall comfort.

LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women

LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.

Why Universal Health Services (UHS) is Poised to Beat Earnings Estimates Again

Universal Health Services (UHS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation

Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.

Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow

Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.

Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View

Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Thermo Fisher (TMO) Q4 Earnings Top Estimates, Gross Margin Down

Strength in PPI business contributed to Thermo Fisher's (TMO) fourth-quarter revenue growth.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

Investors are optimistic about Hologic (HOLX) owing to its strength in the Breast Health and GYN Surgical segments.

Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increased, with earnings and revenues beating estimates.

Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook

Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?

Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.

Charles River (CRL) Launches Animal-Free Endotoxin Test

Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.

ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries

ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.

Here's Why Universal Health Services (UHS) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment

Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.

Bruker (BRKR) to Advance in Lab Automation With New Buyout

This strategic move positions Bruker (BRKR) to further strengthen its Project Accelerate 2.0 initiative, focusing on "Assays, Software, and Aftermarket."

AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment

AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.

BD (BDX) Collaborates With Hamilton to Benefit Researchers

Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.

Why Universal Health Services (UHS) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?

Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.

Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform

Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.

Fast-paced Momentum Stock Universal Health Services (UHS) Is Still Trading at a Bargain

Universal Health Services (UHS) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Dexcom (DXCM) Set to Solidify Its Business Throughout EMEA

Dexcom (DXCM), opening a new manufacturing facility in the West of Ireland, is expected to boost production of rtCGM sensors and create employment.

McKesson (MCK) Set to Sell Canadian Rexall Pharmacy Group

McKesson (MCK) is seeking buyers for the Canadian Rexall Pharmacy Group. The business is currently amid its second round of offers, with no set deadline for submissions.